TBAJ-587

Phase 2Small molecule

GGlobal Alliance for TB Drug Development

TBAJ-587 is one of 9 small molecule programs targeting Tuberculosis, Pulmonary. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tuberculosis, PulmonaryNot yet recruiting

Tuberculosis, PulmonaryPhase 2

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Tuberculosis, Pulmonary

#DrugCompanyPhaseTrials

Zyvox

Pfizer

Phase 2

2 2

Lamprene

Novartis

Phase 2

1 3

TB Alliance

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

4 4

Sirturo

WWim Janssens

Phase 2

3 5

Deltyba

Otsuka

Phase 2

1 6

Ganfeborole

UUniversity College, London

Phase 2

1 7

Avelox

Bayer

Preclinical

3 8

Sorfequiline

GGlobal Alliance for TB Drug Development

Phase 2

1 9

TBAJ-587

GGlobal Alliance for TB Drug Development

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Tuberculosis, Pulmonary

NCT07773610

Clinical

Trials by Indication[1]

Adult1 trial

Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults

Completed·GGlobal Alliance for TB Drug Development·Phase 1·NCT04890535·106 enrolled

Tuberculosis, Pulmonary1 trial

A Phase 2, Randomised, Controlled, Multicentre Two-Part Trial Assessing the Safety and Efficacy of TBAJ-587 as Part of a Combination Regimen in Newly Diagnosed, Drug-Sensitive, Sputum-Positive Pulmonary Tuberculosis

Not yet recruiting·TTASK Applied Science·Phase 2·NCT07773610·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TBAJ-587. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TBAJ-587 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TBAJ-587. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Global Alliance for TB Drug Development company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGlobal Alliance for TB Drug Development

TBAJ-587

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Adult1 trial

Tuberculosis, Pulmonary1 trial

References

Drug Info

Quick Facts

Related News